Apply here
Instituto De Oncología Intervencionista  en

Interventional Oncology

Treatment of cancer using minimally invasive procedures performed under image guidance date back to the birth of Interventional Radiology in the 1960s. The first arterial embolizations of kidney and liver tumors were performed back then; the aim was to alleviate symptoms associated with hormones, reduce bleeding, and relieve pain. This period also yielded the first studies of intra-arterial chemotherapy delivery as an option for the treatment of metastatic liver diseases.

Since the early 1990s, minimally invasive image-guided therapies used in interventional oncology to treat hepatocellular carcinoma have continued to evolve. In addition, the range of applications has been extended to the treatment of liver metastases from colorectal cancer, neuroendocrine tumors, cholangiocarcinoma, breast cancer, melanoma and sarcoma.

Intra-arterial treatment is continuously performed in different countries all over the world (see publications). Its advantages include being less painful and debilitating for the patient, allowing faster convalescence, and causing fewer overall side effects and complications.

What IDOI does differently is the preparation, mixing, dosage and sequential administration of the different medications that integrates the treatment’s model. It also uses the intrathecal route to administer medications.

The interventional oncology that IDOI performs consists in a puncture made in the femoral artery through which a micro catheter is inserted and directed by fluoroscopy to the blood supply site of the tumor. 

The risks related with the procedure are minimal and imply the formation of a hematoma in the puncture site (less than 5%) and a possible vascular event such as a stroke (less than 0.7%). The other part of the procedure consists in making a lumbar puncture after the intra-arterial treatment with the application of medications.

The inherent risks of this procedure are pain in the puncture site, the formation of a hematoma and some irritation of the cauda equine (radiculitis) that occurs in less than 1% of the cases.

All medication used by IDOI are approved by Cofepris and FDA.